Werewolf Therapeutics, Inc.

Contributing Author

Recent Articles by Werewolf Therapeutics, Inc.

Oct-08	Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer HOWL GlobeNewswire
Oct-03	Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting HOWL GlobeNewswire
Sep-02	Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference HOWL GlobeNewswire
Aug-14	Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update HOWL GlobeNewswire
Jul-09	Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit HOWL GlobeNewswire
Jun-12	Werewolf Therapeutics to Participate in the BIO International Convention HOWL GlobeNewswire
May-29	Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference HOWL GlobeNewswire
May-20	HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124 HOWL GlobeNewswire
May-13	Werewolf Therapeutics to Participate in Hanson Wade's 6th Annual Cytokine-Based Drug Development Summit HOWL GlobeNewswire
May-08	Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update HOWL GlobeNewswire
May-05	Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting HOWL GlobeNewswire
May-05	Werewolf Therapeutics to Participate in Upcoming Investor Conferences HOWL GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.